Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13.
Azarias Da Silva M, Nioche P, Soudaramourty C, Bull-Maurer A, Tiouajni M, Kong D, Zghidi-Abouzid O, Picard M, Mendes-Frias A, Santa-Cruz A, Carvalho A, Capela C, Pedrosa J, Castro AG, Loubet P, Sotto A, Muller L, Lefrant JY, Roger C, Claret PG, Duvnjak S, Tran TA, Tokunaga K, Silvestre R, Corbeau P, Mammano F, Estaquier J. Azarias Da Silva M, et al. Among authors: capela c. Sci Adv. 2023 Aug 4;9(31):eadg2122. doi: 10.1126/sciadv.adg2122. Epub 2023 Aug 4. Sci Adv. 2023. PMID: 37540749 Free PMC article.
Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+β7 integrin+ T cells and anti-SARS-CoV-2 IgA response.
Santa Cruz A, Mendes-Frias A, Azarias-da-Silva M, André S, Oliveira AI, Pires O, Mendes M, Oliveira B, Braga M, Lopes JR, Domingues R, Costa R, Silva LN, Matos AR, Ângela C, Costa P, Carvalho A, Capela C, Pedrosa J, Castro AG, Estaquier J, Silvestre R. Santa Cruz A, et al. Among authors: capela c. Nat Commun. 2023 Mar 30;14(1):1772. doi: 10.1038/s41467-023-37368-1. Nat Commun. 2023. PMID: 36997530 Free PMC article.
Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis.
Seifer G, Arun T, Capela C, Laureys G, Jones E, Dominguez-Castro P, Sanchez-de la Rosa R, Hiltl S, Iaffaldano P. Seifer G, et al. Among authors: capela c. Mult Scler Relat Disord. 2023 Aug;76:104770. doi: 10.1016/j.msard.2023.104770. Epub 2023 May 26. Mult Scler Relat Disord. 2023. PMID: 37307690 Free article.
Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
Santos M, Sequeira J, Abreu P, Guerreiro R, Santos M, Ferreira J, Brum M, Ladeira F, Leitão L, Dias R, Sá MJ, Salgado V, Capela C, de Sá J. Santos M, et al. Among authors: capela c. Clin Neuropharmacol. 2023 May-Jun 01;46(3):105-111. doi: 10.1097/WNF.0000000000000552. Epub 2023 Apr 11. Clin Neuropharmacol. 2023. PMID: 37191564
HBV and VZV seroprotection loss in MS patients under DMT.
Ladeira F, Oliveira T, Soares M, Araujo C, Sousa A, Brum M, Sequeira J, Capela C. Ladeira F, et al. Among authors: capela c. Mult Scler Relat Disord. 2023 Feb;70:104490. doi: 10.1016/j.msard.2022.104490. Epub 2022 Dec 28. Mult Scler Relat Disord. 2023. PMID: 36621160
42 results